Skip to main content

Effect of ramipril on the incidence of diabetes.

Publication ,  Journal Article
DREAM Trial Investigators; Bosch, J; Yusuf, S; Gerstein, HC; Pogue, J; Sheridan, P; Dagenais, G; Diaz, R; Avezum, A; Lanas, F; Probstfield, J ...
Published in: N Engl J Med
October 12, 2006

BACKGROUND: Previous studies have suggested that blockade of the renin-angiotensin system may prevent diabetes in people with cardiovascular disease or hypertension. METHODS: In a double-blind, randomized clinical trial with a 2-by-2 factorial design, we randomly assigned 5269 participants without cardiovascular disease but with impaired fasting glucose levels (after an 8-hour fast) or impaired glucose tolerance to receive ramipril (up to 15 mg per day) or placebo (and rosiglitazone or placebo) and followed them for a median of 3 years. We studied the effects of ramipril on the development of diabetes or death, whichever came first (the primary outcome), and on secondary outcomes, including regression to normoglycemia. RESULTS: The incidence of the primary outcome did not differ significantly between the ramipril group (18.1%) and the placebo group (19.5%; hazard ratio for the ramipril group, 0.91; 95% confidence interval [CI], 0.81 to 1.03; P=0.15). Participants receiving ramipril were more likely to have regression to normoglycemia than those receiving placebo (hazard ratio, 1.16; 95% CI, 1.07 to 1.27; P=0.001). At the end of the study, the median fasting plasma glucose level was not significantly lower in the ramipril group (102.7 mg per deciliter [5.70 mmol per liter]) than in the placebo group (103.4 mg per deciliter [5.74 mmol per liter], P=0.07), though plasma glucose levels 2 hours after an oral glucose load were significantly lower in the ramipril group (135.1 mg per deciliter [7.50 mmol per liter] vs. 140.5 mg per deciliter [7.80 mmol per liter], P=0.01). CONCLUSIONS: Among persons with impaired fasting glucose levels or impaired glucose tolerance, the use of ramipril for 3 years does not significantly reduce the incidence of diabetes or death but does significantly increase regression to normoglycemia. (ClinicalTrials.gov number, NCT00095654 [ClinicalTrials.gov].).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

October 12, 2006

Volume

355

Issue

15

Start / End Page

1551 / 1562

Location

United States

Related Subject Headings

  • Ramipril
  • Middle Aged
  • Male
  • Incidence
  • Humans
  • Glucose Intolerance
  • General & Internal Medicine
  • Female
  • Fasting
  • Double-Blind Method
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DREAM Trial Investigators, Bosch, J., Yusuf, S., Gerstein, H. C., Pogue, J., Sheridan, P., … Holman, R. R. (2006). Effect of ramipril on the incidence of diabetes. N Engl J Med, 355(15), 1551–1562. https://doi.org/10.1056/NEJMoa065061
DREAM Trial Investigators, Jackie Bosch, Salim Yusuf, Hertzel C. Gerstein, Janice Pogue, Patrick Sheridan, Gilles Dagenais, et al. “Effect of ramipril on the incidence of diabetes.N Engl J Med 355, no. 15 (October 12, 2006): 1551–62. https://doi.org/10.1056/NEJMoa065061.
DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006 Oct 12;355(15):1551–62.
DREAM Trial Investigators, et al. “Effect of ramipril on the incidence of diabetes.N Engl J Med, vol. 355, no. 15, Oct. 2006, pp. 1551–62. Pubmed, doi:10.1056/NEJMoa065061.
DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006 Oct 12;355(15):1551–1562.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

October 12, 2006

Volume

355

Issue

15

Start / End Page

1551 / 1562

Location

United States

Related Subject Headings

  • Ramipril
  • Middle Aged
  • Male
  • Incidence
  • Humans
  • Glucose Intolerance
  • General & Internal Medicine
  • Female
  • Fasting
  • Double-Blind Method